TY - JOUR
PY - 2016//
TI - The characterization of drug and alcohol use among senior drivers fatally injured in U.S. motor vehicle collisions, 2008-2012
JO - Traffic injury prevention
A1 - Rudisill, Toni M.
A1 - Zhu, Motao
A1 - Abate, Marie A.
A1 - Davidov, Danielle M.
A1 - Delagarza, Vincent
A1 - Long, D. Leann
A1 - Sambamoorthi, Usha
A1 - Thornton, J. Doug
SP - 788
EP - 795
VL - 17
IS - 8
N2 - OBJECTIVE: Adults 65 years of age and older comprise the fastest growing demographic in the United States. As substance use is projected to increase in this population, there is concern that more seniors will drive under the influence of impairing drugs. The purpose of this analysis was to characterize the drug and alcohol usage among senior drivers fatally injured (FI) in traffic collisions.
METHODS: Data from the Fatality Analysis Reporting System were analyzed from 2008-2012. Commonly used classes and specific drugs were explored. Rates of drug use, multiple drugs, concomitant drug and alcohol use, and alcohol use alone were generated using Poisson regression with robust error variance estimation. Rates were compared to a reference population of FI middle-aged drivers (30 to 50 years old) using rate ratios.
RESULTS: Drug use among FI senior drivers occurred in 20.0% of those tested. Among drug-positive FI senior drivers, narcotics and depressants were frequent. The prevalence of testing positive for any drug, multiple drugs, combined drug and alcohol, and alcohol use alone among FI seniors were 47% less (RR = 0.53, 95% CI 0.47, 0.62), 59% less (RR = 0.41, 95% CI 0.34, 0.51), 87% less (RR = 0.13, 95% CI 0.09, 0.19) and 77% less (RR = 0.23, 95% CI 0.19, 0.28), respectively, compared to FI middle-aged drivers.
CONCLUSIONS: While overall drug use is less common among FI senior drivers relative to FI middle-aged drivers, driving under the influence of drugs may be a relevant traffic safety concern in a portion of this population.
Language: en
LA - en SN - 1538-9588 UR - http://dx.doi.org/10.1080/15389588.2016.1165809 ID - ref1 ER -